Carbidopa

Carbidopa ((S) - (-) -Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth[1][2].

Product Specifications

CAS Number

[28860-95-9]

Product Name Alternative

(S) - (-) -Carbidopa

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Aryl Hydrocarbon Receptor

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Carbidopa.html

Purity

99.84

Solubility

DMSO : 10 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

OC1=C(O)C=CC(CC(NN)(C(O)=O)C)=C1

Molecular Formula

C10H14N2O4

Molecular Weight

226.23

Precautions

H302, H315, H319, H335

References & Citations

[1]Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM) . Biochem J. 2017;474 (22) :3763-3765. Published 2017 Nov 6.|[2]Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43 (12) :587-591.